<PubmedArticle>
<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
<PMID Version="1">27080209</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>03</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-1753</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>27</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2016</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of dermatological treatment</Title>
<ISOAbbreviation>J Dermatolog Treat</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.</ArticleTitle>
<Pagination>
<MedlinePgn>467-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3109/09546634.2016.1157257</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Phosphodiesterase type 4 (PDE4) inhibition is a well-known anti-inflammatory mechanism. However, the clinical use of PDE4 inhibitors has been compromised by the occurrence of mechanism-associated adverse reactions, which often limit the maximum tolerated dose. To minimize systemic exposure, a topically active PDE4 inhibitor with low transdermal bioavailability could be clinically useful. The purpose of this study was to evaluate the efficacy of a novel topical PDE4 inhibitor, E6005, in patients with atopic dermatitis.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, investigator-blinded, vehicle-controlled, multiple ascending dose study included 40 adult male patients with atopic dermatitis, who were randomly assigned to 10 days of treatment with either E6005 ointment (0.01, 0.03, 0.1 or 0.2%) or vehicle ointment.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 81 patients screened, 40 who had typical lesions on their posterior trunk were randomized into the study. One patient receiving 0.03% E6005 treatment discontinued because of acute gout and one receiving vehicle treatment discontinued because of progression of atopic dermatitis. The targeted lesion severity scores decreased in a concentration-dependent manner in patients treated with E6005. This drop was significant in the 0.2% E6005 ointment treatment group (mean percent change: -54.30%, p = 0.007).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">E6005 ointment showed anti-inflammatory efficacy in adult patients with atopic dermatitis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ohba</LastName>
<ForeName>Fuminori</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>a Eisai Product Creation Systems, Eisai Co Ltd , Tokyo , Japan ;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsuki</LastName>
<ForeName>Shunji</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>b Sugioka Memorial Hospital Clinical Research Center , Fukuoka , Japan ;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Imayama</LastName>
<ForeName>Shuhei</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>c Imayama Shuhei Clinic and Laboratory , Fukuoka , Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsuguma</LastName>
<ForeName>Kyoko</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>b Sugioka Memorial Hospital Clinical Research Center , Fukuoka , Japan ;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hojo</LastName>
<ForeName>Seiichiro</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>a Eisai Product Creation Systems, Eisai Co Ltd , Tokyo , Japan ;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nomoto</LastName>
<ForeName>Maiko</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>a Eisai Product Creation Systems, Eisai Co Ltd , Tokyo , Japan ;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Akama</LastName>
<ForeName>Hideto</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>a Eisai Product Creation Systems, Eisai Co Ltd , Tokyo , Japan ;</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>04</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Dermatolog Treat</MedlineTA>
<NlmUniqueID>8918133</NlmUniqueID>
<ISSNLinking>0954-6634</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009824">Ointments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058988">Phosphodiesterase 4 Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010795">Phthalic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C583128">methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000279">Administration, Cutaneous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003876">Dermatitis, Atopic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009824">Ointments</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058988">Phosphodiesterase 4 Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010795">Phthalic Acids</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">Atopic eczema</Keyword>
<Keyword MajorTopicYN="Y">clinical trial</Keyword>
<Keyword MajorTopicYN="Y">phosphodiesterase 4 inhibitor</Keyword>
<Keyword MajorTopicYN="Y">topical treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27080209</ArticleId>
<ArticleId IdType="doi">10.3109/09546634.2016.1157257</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>